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Abstract
The P2X7 receptor (P2X7R) is an ATP-gated cation channel with a critical role in many physiological and pathological
processes, and shows prominent functional differences across mammalian species, exemplified by larger current responses of
the rat (r) P2X7R to ATP and its analogue BzATP and a greater sensitivity to agonists compared with the human (h) P2X7R.
Here, we showed that substitution of Val87 residue in the extracellular domain of the hP2X7R with isoleucine in the rP2X7R
increased the current responses of the hP2X7R to both ATP and BzATP. Conversely, introduction of reciprocal I87Vmutation in
the rP2X7R led to a noticeable but statistically insignificant reduction in the current responses of the rP2X7R toATP and BzATP.
The mutations did not affect the sensitivity of the human and rat P2X7Rs to ATP and BzATP. These results suggest a contri-
bution of Val/Ile87 in agonist-induced current responses of human and rat P2X7Rs, which helps to better understand the
molecular determinants for species-dependent function of the mammalian P2X7Rs.
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Introduction
P2X receptors (P2XRs) comprise a group of seven trimeric,
nonselective cation channels that are selectively activated by
extracellular ATP [1]. The mammalian P2X7 receptor
(P2X7R) is a key mediator of responses induced by high levels
of ATP associated with tissue inflammation and damage, hyp-
oxia, and emotional stress, and plays a critical role in diverse
pathologies such as inflammatory disorders, neurodegenerative
diseases, mood disorders, and cancers [2–6]. The P2X7Rs of
different species exhibit striking differences in functional prop-
erties; it has been well documented that the agonist
concentrations evoking half of the maximal response (EC50)
for ATP and its analogue BzATP are several-fold higher at
the human (h) P2X7R than at the rat (r) P2X7R and, addition-
ally, agonist-evoked responses from the hP2X7R are smaller
than those from the rP2X7R [7–10]. Previous studies identified
two residues, one at position 155 in the extracellular domain
and the other at 348 in the second transmembrane domain, as
important determinants for the difference in agonist-induced
current responses between human and rat P2X7Rs [11, 12].
In this short communication, we report residue at position 87
in the extracellular domain that contributes the current re-
sponses of the human and rat P2X7Rs to ATP and BzATP.
Methods
Homology modelling and ligand docking The structures of
the rP2X7R in the closed and ATP-bound open states
(Protein Data Bank code 6U9V and 6U9W, respectively) were
used to produce the structural models of the hP2X7R.
Modeller version 9.12 [13] was used to produce these models,
which were analysed using MolProbity [14] as detailed in our
previous studies [15, 16]. AutoDock version 4.2 [17] was used
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to dock ATP and BzATP to a cavity file consisting of a 15-Å
sphere surrounding the P2X7R ATP-binding site and affinity
grid files were generated using the auxiliary program
AutoGrid.
Site-directed mutagenesis The cDNA for wild-type (WT) hu-
man or rat P2X7 receptor subunit with an EE epitope in the C-
terminus was subcloned in pcDNA3.1 vector and used in our
previous studies [11, 15]. Point mutations were introduced
using a PCR-based protocol we previously described [18]
(for more details, see supplemental information) and con-
firmed by commercial sequencing (Beckman Coulter
Genomics).
Expression of P2X7R and patch-clamp recordingWT and mu-
tant P2X7Rs were transiently expressed in human embryonic
kidney (HEK) 293 cells, and agonist-induced whole-cell cur-
rents were recorded using patch-clamp technique, as previous-
ly described [11, 15]. The EC50 values were derived by fitting
the concentration-response relationship curves to the Hill
equation [14]. Further details are presented in supplemental
information. Agonist-induced currents recorded in parallel ex-
periments were used for comparisons.
Data analysis All results, where appropriate, are presented as
the mean ± standard error of the mean (SEM).
Statistical analysis was carried out using Student’s t test for
two groups or one-way analysis of variance test and Tukey’s
post hoc test for more than two groups, with the difference
considered to be significant at p < 0.05.
Results
Effects of mutating residues in the extracellular
domain in hP2X7R on BzATP-induced currents
Sequence analysis of the extracellular domain of the human
(and monkey) versus the rat (and mouse) P2X7Rs [7, 19, 20]
identified 25 residues of interest (Fig. 1S). We chose a subset
of 13 residues and substituted each of them in the hP2X7R
with that in the rP2X7R, expressed the mutant hP2X7Rs in
HEK293 cells in parallel with theWT human and rat P2X7Rs,
and assessed the mutational effects on the current responses to
300 μM BzATP, a maximal concentration (Fig. 1a, b). As
anticipated, BzATP elicited much smaller currents from
WT-hP2X7R than WT rP2X7R (Fig. 1b). Seven mutations
had no effect on, and five mutations reduced, BzATP-
induced currents (Fig. 1b). V87I was the only mutation in-
creasing BzATP-induced currents, with the mean amplitude
significantly higher than that from WT hP2X7R and compa-
rable with that from WT rP2X7R (Fig. 1b). Val/Ile87 is
located in the top part of the extracellular domain of the re-
ceptors (Fig. 1c, d).
Effects of reciprocally mutating residues at position
87 in human and rat P2X7Rs on agonist-evoked
currents
To better understand the contribution of Val87 in the hP2X7R
and Ile87 in the rP2X7R in species difference, we next exam-
ined the effect of V87I mutation on the hP2X7R and the effect
of reciprocal mutation I87V on the rP2X7R in their current
responses to a range of BzATP concentrations (Fig. 2a, b).
BzATP at all concentrations elicited larger currents from
hP2X7R-V87I than WT hP2X7R (top two panels in Fig.
2a). The mean maximal current amplitude from hP2X7R-
V87I was significantly larger than that from WT hP2X7R
(Fig. 2b). Conversely, BzATP at all concentrations evoked
smaller currents from rP2X7R-I87V relative to WT rP2X7R
(bottom two panels in Fig. 2a). The mean maximal current
amplitude from rP2X7R-I87V was smaller than that from
WT rP2X7R, but the difference did not reach statistical sig-
nificance (Fig. 2b). We also examined the effects of both
mutations on the current responses of human and rat
P2X7Rs to a range of ATP concentrations (Fig. 2c, d).
Similarly, ATP at all concentrations evoked larger currents
from hP2X7R-V87I than from WT hP2X7R, with the maxi-
mal current amplitude from hP2X7R-V87I significantly larger
than that from WT hP2X7R (Fig. 2c, d). Introduction of the
I87V mutation in the rP2X7R decreased the current responses
to ATP at all concentrations. The maximal current amplitude
from rP2X7R-I87V was smaller than that from WT rP2X7R
and again the reduction was not statistically significant (Fig.
2d). Collectively, these results indicate that reciprocal muta-
tion of the residue at position 87 interchanged the current
responses of the human and rat P2X7Rs to both BzATP and
ATP, albeit with the human-to-rat mutation resulting in more
prominent or significant effects.
It is known that the hP2X7R is less sensitive to agonists
than the rP2X7R [7–11]. We further examined the effects of
reciprocally mutating the residue at position 87 on the sensi-
tivity of human and rat P2X7Rs to BzATP and ATP by deter-
mining the EC50 values. The BzATP EC50 for WT hP2X7R
was approximately 5-fold greater than that for WT rP2X7R
(Fig. 2e) and the ATP EC50 for WT hP2X7R was 3-folder
higher than that for WT rP2X7R (Fig. 2f). The BzATP EC50
for hP2X7R-V87I was similar to that for WT hP2X7R, and
the BzATP EC50 for rP2X7R-I87V was close to that for WT
P2X7R (Fig. 2e). Similarly, the ATP EC50 for both hP2X7R-
V87I and rP2X7R-I87V showed no difference to that for re-
spective WT receptors (Fig. 2f). These results indicate no
effect of the mutations on the sensitivity of the human and
rat P2X7Rs to both BzATP and ATP.
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Discussion
The mammalian P2X7Rs are well known for their striking
inter-species functional differences, as shown by the
agonist-induced current responses and agonist sensitivity
[7, 10, 11]. To gain a better understanding of the molec-
ular determinants for such species difference between the
human and rat P2X7Rs, we selected 13 residues in the
extracellular domains and examined the effects of
substituting individual residue in the hP2X7R with that
in the rP2X7R on the current responses to BzATP at a
maximal concentration (Fig. 1a, b). All the mutations,
except for V87I, led to either no change or a reduction
in BzATP-induced current response. Here, we did not
further examine these mutants and how these mutations
induced loss of function mechanistically remains unclear.
V87I increased BzATP-induced hP2X7R-mediated cur-
rents, with the current amplitude close to that from WT
rP2X7R (Fig. 1b). We further examined this gain-of-
function mutation in the hP2X7R and the reciprocal
I87V mutation in the rP2X7R in terms of their effects
on the agonist-induced current amplitude and the agonist
sensitivity at the human and rat P2X7Rs. We confirmed
the reported differences in the current amplitude and the
sensitivity to BzATP and ATP between human and rat
P2X7Rs (Fig. 2a–d). Importantly, our results showed that
the current responses from V87I-hP2X7R to both BzATP
(Fig. 2a, b) and ATP (Fig. 2c, d) were consistently higher
than those from WT-hP2X7R. Conversely, introduction of
the I87V mutation in the rP2X7R reduced the current
responses to both BzATP (Fig. 2a, b) and ATP (Fig.
2c, d), though the differences were statistically insignifi-
cant. Moreover, our results showed no effect of V87I in
the hP2X7R or I87V in the rP2X7R on the EC50 values
for ATP and BzATP (Fig. 2e, f). Collectively, these re-
sults suggest that Val/Ile87 residue mainly influences the
difference in agonist-induced current responses between
human and rat P2X7Rs.
The recently determined rP2X7R structure [21] pro-
vides useful information to understand or rule out the
mechanisms by which Val/Ile87 residue contributes to
the mutational effects on human and rat P2X7Rs. This
residue is positioned distant to the agonist-binding site
in the human, rat, and mouse P2X7Rs (Fig. 1c, d and
Fig. S2A) [22], and thus, the mutations are unlikely
to influence agonist binding, which is consistent with no
effect on the sensitivity to ATP or BzATP (Fig. 2e, f). As
we previously showed, Ala/Thr348 in the second trans-
membrane domain lining the ion-conducting pore contrib-
utes to the difference in the current responses of human
and rat P2X7Rs to ATP via affecting the ion conductance
[11]. This possibility can be ruled out for Val/Ile87 be-
cause it is far away from the transmembrane pore. Our
previous study suggests that His/Tyr155 in the extracellu-
lar domain differentially modulates the cell surface ex-
pression of human and rat P2X7Rs and therefore contrib-
utes to the difference in the current responses of human
and rat P2X7Rs to ATP [11]. Immunofluorescent imaging
Fig. 1 Effects of mutating residues in the extracellular domain that differ
between human and rat P2X7Rs on BzATP-induced hP2X7R-mediated
currents. a Representative currents evoked by 300 μM BzATP in
HEK293 cells expressing wild-type (WT) human (h) P2X7R, WT rat
(r) P2X7R, or mutant hP2X7R as indicated. b Summary of mean
BzATP-induced current amplitude for indicated P2X7Rs. n = 3–4 cells
for each case, 8–9 cells for hP2X7 and rP2X7 controls. *p < 0.05 and
**p < 0.01 compared with WT hP2X7R. ##p < 0.01 indicating difference
between human and rat WT P2X7Rs. c Structural models of the hP2X7R
showing the location of Val87, represented as spheres, in closed state
(left) and ATP-bound open state (right). d Zoomed-in view of Val87
(V87) in the hP2X7R (left) and Ile87 (I87) in the rP2X7R (right), relative
to the ATP-binding site
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revealed no noticeable mutational effect on the expression
and subcellular distribution of human and rat P2X7Rs
(Fig. S3). The location of Val/Ile87 is at the top of the
‘head’ region of the P2X7Rs, with Val87 in the hP2X7R
in the vicinity of residues including Glu186 [23] and
Gln187 [24] (Fig. S2B), mutation of which were shown
to affect hP2X7R activation, prompting us to hypothesise
that Val/Ile87 may impact the closure of the ATP-binding
vestibule that induces the conformational changes essen-
tial for channel opening [25]. Further investigations are
required to examine this hypothesis. Residues flanking
Val87 in the hP2X7R were reported to participate in allo-
steric binding of AZ10606120, a human and rat P2X7R
antagonist [26]. It would be interesting to examine wheth-
er Val/Ile87 contributes to the action of antagonists
exhibiting species differences.
In summary, this study reports contribution of extracellular
Val/Ile87 residue in agonist-induced current responses of hu-
man and rat P2X7Rs, which helps us better understand the
molecular determinants for species difference in the function
of the mammalian P2X7Rs.
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